Trump Buys SpaceX Shares After Record IPO 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Nvidia Options Price in $280 Billion Earnings Swing 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Tesla Raises Cybertruck Prices by $5,000 in US 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Add as a preferred source on Google
RANCHO CORDOVA, Calif., April 25, 2018 -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL) today announced that the Company will be exhibiting its full suite of cellular processing solutions, including CAR-TXpress™ for the semi-automated manufacture of CAR-T cell therapies, X-BACS™ for cell isolation and other X-Series™ kits, at the following cell therapy conferences in May:
- International Society of Cellular Therapy 2018 Annual Meeting
May 2 – 5, 2018
Booth: 322
Palais des congrès de Montréal
1001, Place Jean-Paul-Riopelle
Montreal, Canada
For more information: www.isct2018.com
- American Society of Gene and Cell Therapy 2018 Annual Meeting
May 16 – 19, 2018
Booth: 417
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
For more information: www.asgct.org/meetings-workshops/annual-meeting
- Phacilitate Automation Special Interest Group 2018
May 30 – 31, 2018
The Grove
Chandler’s Cross,
Watford WD3 4TG, Hertfordshire
London, UK
For more information: www.phacilitateautomation.com
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform that addresses the critical unmet need for better cellular manufacturing and controls for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
